Toronto, Ontario – The Newswire – August 10,  2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is thrilled to announce that Ventripoint and Ascend Cardiovascular, a leading provider of cardiovascular IT solutions, have solidified a strategic collaboration. The two companies have signed a letter of intent to explore joint research and development initiatives, knowledge sharing, and combining  efforts to bring innovative AI-based solutions to the market.

Ascend Cardiovascular has over two decades of experience in cardiovascular IT and is an expert in cardiology workflow. Ascend’s clinical reporting, device interfaces, and analytics are used daily by some of the top institutions and hospital systems in North America.

The teamwork  between Ventripoint and Ascend leverages the strengths and expertise of both Ascend and Ventripoint to enhance cardiovascular diagnostics and improve patient care. By combining the capabilities of Ventripoint and Ascend, both companies aim to develop and integrate solutions to improve diagnostic accuracy, streamline workflows, and enhance patient experience. Ascend intends to resell Ventripoint products developed through this partnership and integrated with Ascend’s cardiovascular IT platform.

“This collaboration with Ascend Cardiovascular is part of Ventripoint’s mission to elevate cardiac care by providing better tools for clinicians.  We are excited about what the two companies can accomplish by joining efforts,” stated Dr. Alvira Macanovic, President & CEO of Ventripoint.  

This coordination  will include exploring joint research and development initiatives aimed at enhancing existing cardiovascular diagnostic technologies and identifying new opportunities.  This may include joint projects, knowledge sharing, and collaborative efforts to seek regulatory approvals and commercialize new products or services including, where applicable, co-marketing and sales support activities

"Ascend is on a mission to provide a fully integrated, best-of-breed cardiovascular workflow solution to its customers. Integration with Ventripoint's innovative solution for 3D visualization will provide tremendous value to pediatric and adult echocardiographers in the care of their most complex patients," stated Dr. Jeff Soble, CEO of Ascend Cardiovascular.

Both Ventripoint and Ascend are excited about the potential impact of this collaboration within the field of cardiovascular diagnostics. Ascend brings their clinical and industry knowledge, along with its proprietary structured reporting, and its echocardiogram DICOM viewer to the collaboration.  Ventripoint brings its proprietary AI-based diagnostic technologies, research capabilities, and technical expertise in cardiovascular imaging and analysis.  By combining the unique expertise and resources of both companies, new solutions can be made that address existing challenges within the industry.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.  Learn more:  www.ventripoint.com. 

About Ascend Cardiovascular

ASCEND Cardiovascular is a leader in innovating cardiovascular solutions that empower the provider community to improve cardiovascular care. Designed with openness in mind, our solutions integrate with EHRs, medical devices, and other systems to deliver seamless workflows that span procedure types and modalities. A complete cardiovascular solution, ASCEND provides structured reporting, image visualization, collaboration, and analytics that improve efficiency, outcomes, and ROI. With decades of experience and a practicing cardiologist at our helm, the ASCEND team brings unparalleled “know how” in cardiology workflow, collaboration, and IT offering limitless opportunities to improve clinical, operational, and quality performance. Learn more: www.ascendcv.com.

For further information, please contact:

Jonathan Robinson CFA

This email address is being protected from spambots. You need JavaScript enabled to view it.

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.